Last $0.01 USD
Change Today -0.0009 / -6.52%
Volume 2.1K
DGEN On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

deltagen inc (DGEN) Snapshot

Open
$0.0039
Previous Close
$0.01
Day High
$0.01
Day Low
$0.0039
52 Week High
07/26/13 - $0.05
52 Week Low
10/18/13 - $0.0007
Market Cap
501.2K
Average Volume 10 Days
3.4K
EPS TTM
$-1.54
Shares Outstanding
38.9M
EX-Date
05/17/07
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DELTAGEN INC (DGEN)

Related News

No related news articles were found.

deltagen inc (DGEN) Related Businessweek News

No Related Businessweek News Found

deltagen inc (DGEN) Details

Deltagen, Inc. provides drug discovery tools and services to the biopharmaceutical industry and to the academic research community in the United States. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was founded in 1997 and is headquartered in San Mateo, California.

deltagen inc (DGEN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

deltagen inc (DGEN) Key Developments

Deltagen, Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2013

Deltagen Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2013. The company's consolidated revenues for the three months ended March 31, 2013 totaled $0.194 million. The revenues in the first quarter of 2013 were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company's DeltaOne(TM) program. The consolidated revenues for the period included $0.040 million for Xenopharm Inc. Consolidated net losses before provision for income taxes for the three months ended March 31, 2013 were $0.541 million, which included a net loss of $0.063 million from operations and a recognized net loss of $0.478 million from investments made by the Company in Benten BioServices Inc., which was accounted for using the Equity Method of Accounting. Income from operations was $63,000. loss before provision for income taxes and net loss was $604,000.

Deltagen Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2012

Deltagen Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2012. For the quarter, the company consolidated revenues totaled was $133,000. The revenues in the fourth quarter and in 2012 were attributable to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the company's DeltaOne program. The company's consolidated revenues for the three months ended December 31, 2012 included $88,000 in revenues of Xenopharm Inc. Consolidated net losses before provision for income taxes for the three months ended December 31, 2012 were $677,000 million. Loss from operations was $98,000 for the three months ended December 31, 2012. Net loss was $677,000 for the three months ended December 31, 2012. For the year, the company reported consolidated revenue of $1,054,000. The revenues in the fourth quarter and in 2012 were attributable to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the company's DeltaOne program. The company's consolidated revenues for the year ended December 31, 2012 included $142,000 in revenues of Xenopharm Inc. Consolidated net losses before provision for income taxes for the year ended December 31, 2012 were $1,165,000. Loss from operations was $53,000 for the year ended December 31, 2012. Net loss was $1,165,000 for the year ended December 31, 2012. These consolidated net losses included recognized net losses of $0.579 million and $1.113 million, respectively, or 43.8% of Benten BioServices' net operating losses, which was accounted for using the equity method of accounting.

Deltagen Inc. Reports Consolidated Unaudited Earnings Results for the Third Quarter Ended September 30, 2012

Deltagen Inc. reported consolidated unaudited earnings results for the third quarter ended September 30, 2012. For the quarter, the company reported consolidated revenues totaled $0.211 million. Loss from operations was $0.47 million. Loss before provision for income taxes was $0.581 million. Net loss was $0.581 million. The revenues in the third quarter of 2012 were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the company's DeltaOne(TM) program.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGEN:US $0.01 USD -0.0009

DGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DGEN.
View Industry Companies
 

Industry Analysis

DGEN

Industry Average

Valuation DGEN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELTAGEN INC, please visit www.deltagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.